Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Oct;28(4):449–461. doi: 10.1111/j.1365-2125.1989.tb03526.x

Salicylate pharmacokinetics in patients with rheumatoid arthritis.

S G Owen 1, M S Roberts 1, W T Friesen 1, H W Francis 1
PMCID: PMC1379996  PMID: 2590603

Abstract

1. The pharmacokinetics of salicylic acid (SA) and its major metabolite salicyluric acid (SU) were studied in nine patients with rheumatoid arthritis following a 900 mg oral dose of acetylsalicylic acid and during 6 weeks of chronic administration of enteric coated aspirin (3,900 mg day). Response to therapy was also monitored. 2. The various pharmacokinetic parameters determined in the study were similar to those observed in other single dose salicylate studies amongst healthy volunteers but were not predictive of salicylate concentration in the chronic dose study. 3. Plasma concentrations of SA (total and unbound) were found to decline significantly over the 6 weeks and plasma SU concentrations increased. 4. During the chronic dosing study, there was a significant increase in the Vmax (total and unbound) for the formation of SU, whilst the Km and SU clearance remained constant. Also, the elimination rate constant (k) for salicylate was not significantly affected. 5. Therapeutic response to salicylate therapy was not significantly affected by the decline in SA concentrations.

Full text

PDF
449

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boardman P. L., Hart F. D. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J. 1967 Nov 4;4(5574):264–268. doi: 10.1136/bmj.4.5574.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bochner F., Graham G. G., Cham B. E., Imhoff D. M., Haavisto T. M. Salicylate metabolite kinetics after several salicylates. Clin Pharmacol Ther. 1981 Aug;30(2):266–275. doi: 10.1038/clpt.1981.158. [DOI] [PubMed] [Google Scholar]
  3. Borgå O., Cederlöf I. O., Ringberger V. A., Norlin A. Protein binding of salicylate in uremic and normal plasma. Clin Pharmacol Ther. 1976 Oct;20(4):464–475. doi: 10.1002/cpt1976204464. [DOI] [PubMed] [Google Scholar]
  4. Cham B. E., Ross-Lee L., Bochner F., Imhoff D. M. Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit. 1980;2(4):365–372. [PubMed] [Google Scholar]
  5. Day R. O., Furst D. E., Dromgoole S. H., Paulus H. E. Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. Biopharm Drug Dispos. 1988 May-Jun;9(3):273–283. doi: 10.1002/bod.2510090306. [DOI] [PubMed] [Google Scholar]
  6. Day R. O., Shen D. D., Azarnoff D. L. Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet. 1983 May-Jun;8(3):263–271. doi: 10.2165/00003088-198308030-00005. [DOI] [PubMed] [Google Scholar]
  7. Ekstrand R., Alvan G., Borga O. Concentration dependent plasma protein binding of salicylate in rheumatoid patients. Clin Pharmacokinet. 1979 Mar-Apr;4(2):137–143. doi: 10.2165/00003088-197904020-00006. [DOI] [PubMed] [Google Scholar]
  8. Furst D. E., Gupta N., Paulus H. E. Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formation. J Clin Invest. 1977 Jul;60(1):32–42. doi: 10.1172/JCI108766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Graham G. G., Champion G. D., Day R. O., Paull P. D. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther. 1977 Oct;22(4):410–420. doi: 10.1002/cpt1977224410. [DOI] [PubMed] [Google Scholar]
  10. Gurwich E. L., Raees S. M., Skosey J., Niazi S. Unbound plasma salicylate concentration in rheumatoid arthritis patients. Br J Rheumatol. 1984 Feb;23(1):66–73. doi: 10.1093/rheumatology/23.1.66. [DOI] [PubMed] [Google Scholar]
  11. Günsberg M., Bochner F., Graham G., Imhoff D., Parsons G., Cham B. Disposition of and clinical response to salicylates in patients with rheumatoid disease. Clin Pharmacol Ther. 1984 May;35(5):585–593. doi: 10.1038/clpt.1984.81. [DOI] [PubMed] [Google Scholar]
  12. Ho P. C., Triggs E. J., Bourne D. W., Heazlewood V. J. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol. 1985 May;19(5):675–684. doi: 10.1111/j.1365-2125.1985.tb02695.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Koch-Weser J. Drug therapy. Serum drug concentrations as therapeutic guides. N Engl J Med. 1972 Aug 3;287(5):227–231. doi: 10.1056/NEJM197208032870505. [DOI] [PubMed] [Google Scholar]
  14. Lesko L. J., Narang P. K., Yeager L., Cutler N. R. Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration. Eur J Clin Pharmacol. 1985;28(3):339–345. doi: 10.1007/BF00543334. [DOI] [PubMed] [Google Scholar]
  15. Levy G., Amsel L. P., Elliott H. C. Kinetics of salicyluric acid elimination in man. J Pharm Sci. 1969 Jul;58(7):827–829. doi: 10.1002/jps.2600580705. [DOI] [PubMed] [Google Scholar]
  16. Levy G. Pharmacokinetics of salicylate elimination in man. J Pharm Sci. 1965 Jul;54(7):959–967. doi: 10.1002/jps.2600540703. [DOI] [PubMed] [Google Scholar]
  17. Levy G., Tsuchiya T. Salicylate accumulation kinetics in man. N Engl J Med. 1972 Aug 31;287(9):430–432. doi: 10.1056/NEJM197208312870903. [DOI] [PubMed] [Google Scholar]
  18. Levy G., Vogel A. W., Amsel L. P. Capacity-limited salicylurate formation during prolonged administration of aspirin to healthy human subjects. J Pharm Sci. 1969 Apr;58(4):503–504. doi: 10.1002/jps.2600580432. [DOI] [PubMed] [Google Scholar]
  19. Miller R. R. Deafness due to plain and long-acting aspirin tablets. J Clin Pharmacol. 1978 Oct;18(10):468–471. doi: 10.1002/j.1552-4604.1978.tb01573.x. [DOI] [PubMed] [Google Scholar]
  20. Miners J. O., Grgurinovich N., Whitehead A. G., Robson R. A., Birkett D. J. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol. 1986 Aug;22(2):135–142. doi: 10.1111/j.1365-2125.1986.tb05240.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Netter P., Faure G., Regent M. C., Procknal J. A., Levy G. Salicylate kinetics in old age. Clin Pharmacol Ther. 1985 Jul;38(1):6–11. doi: 10.1038/clpt.1985.124. [DOI] [PubMed] [Google Scholar]
  22. Olsson B. Decreasing serum salicylate concentrations during long-term administration of acetylsalicylic acid in healthy volunteers. Discussion of possible clinical implications. Scand J Rheumatol. 1983;12(2):81–84. doi: 10.3109/03009748309102889. [DOI] [PubMed] [Google Scholar]
  23. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  24. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  25. Roberts M. S., Rumble R. H., Wanwimolruk S., Thomas D., Brooks P. M. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol. 1983;25(2):253–261. doi: 10.1007/BF00543800. [DOI] [PubMed] [Google Scholar]
  26. Rumble R. H., Brooks P. M., Roberts M. S. Metabolism of salicylate during chronic aspirin therapy. Br J Clin Pharmacol. 1980 Jan;9(1):41–45. doi: 10.1111/j.1365-2125.1980.tb04794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rumble R. H., Roberts M. S., Wanwimolruk S. Determination of aspirin and its major metabolites in plasma by high-performance liquid chromatography without solvent extraction. J Chromatogr. 1981 Sep 11;225(1):252–260. doi: 10.1016/s0378-4347(00)80270-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES